Literature DB >> 23896322

Coating with fibronectin and stromal cell-derived factor-1α of decellularized homografts used for right ventricular outflow tract reconstruction eliminates immune response-related degeneration.

Willem Flameng1, Geofrey De Visscher2, Lindsay Mesure2, Hadewich Hermans2, Ramadan Jashari3, Bart Meuris2.   

Abstract

OBJECTIVE: This study assesses the performance and cellular features of decellularized ovine aortic homografts coated with stromal cell-derived factor-1α (SDF-1α) and its natural linker, fibronectin (FN), after implantation in the right ventricular outflow tract of adolescent sheep.
METHODS: Right ventricular outflow tract reconstructions using cryopreserved (n = 7), decellularized (n = 8), and decellularized FN/SDF-1α-coated aortic ovine homografts (n = 6) were performed. Echocardiographic, morphologic, radiographic, histologic, and immunohistochemical examinations were performed 5 months after implantation.
RESULTS: There were no hemodynamic differences between groups, except for the decellularized homografts' tendency to develop more valve regurgitation (3 of 8 grafts had regurgitation >2/4). All decellularized, but coated, grafts had normal hemodynamics. Decellularized valve conduits were less calcified than cryopreserved conduits (P < .05), but coated valve conduits were free of calcification (P < .05). The same was found for pannus in the outflow parts. Immune response (CD45(+), CD45R(+), or CD11b(+) cells) was decreased in decellularized valves compared with cryopreserved grafts, but was virtually absent (P < .05) in coated grafts. Collagen organization and density in the leaflets and walls were decreased in cryopreserved and decellularized valves, but not in coated valves (P < .05). Coating improved re-endothelialization (P < .05).
CONCLUSIONS: Coating of decellularized allografts with FN/SDF-1α prevents cryopreserved heart valve-mediated immune response, conduit calcification, and pannus formation and stimulates re-endothelialization.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23896322     DOI: 10.1016/j.jtcvs.2013.06.022

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

Review 1.  Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions.

Authors:  Daniel Y Cheung; Bin Duan; Jonathan T Butcher
Journal:  Expert Opin Biol Ther       Date:  2015-06-01       Impact factor: 4.388

2.  CD133 antibody conjugation to decellularized human heart valves intended for circulating cell capture.

Authors:  John D Vossler; Young Min Ju; J Koudy Williams; Steven Goldstein; James Hamlin; Sang Jin Lee; James J Yoo; Anthony Atala
Journal:  Biomed Mater       Date:  2015-09-03       Impact factor: 3.715

3.  Syndecan-4 functionalization of tissue regeneration scaffolds improves interaction with endothelial progenitor cells.

Authors:  Harleigh Warner; Yidi Wu; William D Wagner
Journal:  Regen Biomater       Date:  2021-11-29

Review 4.  Recellularization of decellularized heart valves: Progress toward the tissue-engineered heart valve.

Authors:  Mitchell C VeDepo; Michael S Detamore; Richard A Hopkins; Gabriel L Converse
Journal:  J Tissue Eng       Date:  2017-08-25       Impact factor: 7.813

5.  Dichloroacetate inhibits the degeneration of decellularized cardiovascular implants.

Authors:  Agunda Chekhoeva; Sentaro Nakanishi; Yukiharu Sugimura; Mahfuza Toshmatova; Anna Kathrin Assmann; Artur Lichtenberg; Payam Akhyari; Alexander Assmann
Journal:  Eur J Cardiothorac Surg       Date:  2021-12-27       Impact factor: 4.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.